Date:
Wed, 22 Apr 2026 11:39:56 EDT
Content:
The FDA has released a Form 483 following an inspection of Revive Rx LLC, doing business as Revive Rx Pharmacy, located in Houston, Texas. The document outlines specific observations made by federal investigators regarding the facility’s operations.
Issued on March 27, 2026, the Form 483 is used by the FDA to document concerns observed during an onsite inspection. Revive Rx Pharmacy is identified as a producer of sterile drug products, a category that requires strict adherence to safety and quality standards to prevent contamination and ensure patient safety.
The publication of this record in the OII FOIA Electronic Reading Room highlights the FDA’s ongoing oversight of compounding pharmacies. The firm is typically required to respond to these observations with a corrective action plan to address the identified issues and remain in compliance with federal regulations.
Source: FDA Electronic Reading Room
Link:
http://www.fda.gov/about-fda/fda-commissioner/revive-rx-llc-dba-revive-rx-pharmacy-houston-tx-483-issued-3272026
Keywords:
FDA, Revive Rx Pharmacy, Form 483, Houston TX, Sterile Compounding, Pharmacy Inspection